🔎 Trials Near Me

Akèy › Limfom › Utah › Salt Lake City

Etid klinik pou Limfom nan Salt Lake City, UT

11 etid pou Limfom ap chèche patisipan nan sit nan ak bò kote Salt Lake City (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

Ap rekriteFaz 1/2
  • Intermountain Health, Canyons Region, LDS Hospital, Salt Lake City
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06343311

A Resilience-Based Approach to Improve Long-term Quality of Life in Post-treatment Lymphoma Survivorship

Ap rekrite
  • Huntsman Cancer Institute, Salt Lake City
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07013435

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

Ap rekriteFaz 2
  • University of Utah, Salt Lake City
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07221500

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

Ap rekriteFaz 1/2
  • Primary Children's Hospital, Salt Lake City
12 Months – 21 Years · Tout sèks · Mizajou Sep 11, 2026 · NCT04870944

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

Ap rekriteFaz 1/2
  • Huntsman Cancer Institute, Salt Lake City
  • Intermountain Healthcare, Salt Lake City
Laj 18 ak plis · Tout sèks · Mizajou Aug 25, 2026 · NCT05826535

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

Ap rekriteFaz 3
  • Intermountain Healthcare, Salt Lake City
Laj 18 ak plis · Tout sèks · Mizajou Aug 4, 2026 · NCT07188558

Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers

Ap rekriteEtid obsèvasyon
  • Huntsman Cancer Institute, University of Utah, Salt Lake City
Laj 18 ak plis · Tout sèks · Mizajou Jun 1, 2026 · NCT05663502

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

Ap rekriteFaz 1/2
  • Huntsman Cancer Institute, University of Utah, Salt Lake City
Laj 18 ak plis · Tout sèks · Mizajou Apr 16, 2026 · NCT03328078

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

Ap rekriteFaz 1
  • Huntsman Cancer Institute, University of Utah, Salt Lake City
Laj 18 ak plis · Tout sèks · Mizajou Mar 20, 2026 · NCT04830137

Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy

Ap rekrite
  • Huntsman Cancer Institute at University of Utah, Salt Lake City
Laj 21 ak plis · Tout sèks · Mizajou Feb 5, 2026 · NCT07390071

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

Ap rekriteFaz 1/2
  • University of Utah, Salt Lake City
Laj 18 ak plis · Tout sèks · Mizajou Nov 14, 2025 · NCT05643742

Etid Limfom nan lòt vil

Lòt etid nan Salt Lake City

Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.